Publicacións en colaboración con investigadores/as de University of Colorado Cancer Center (2)

2021

  1. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)

    Lung Cancer, Vol. 155, pp. 68-77

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology